by David Brindley | Nov 5, 2012
Recently, in the twilight on a balmy summer’s evening in DC, an irrationally passionate cell therapy war room convened over meze, ouzo and retsina. And considered the meaty question posed by Lonza’s Jon Rowley: “Where do you think you and the cell therapy industry...
by Stacey Johnson | Sep 26, 2012
My grandmother, at 97, is excited about stem cell research because she sees the possibilities. Regenerative medicine IS an exciting field. It’s on the cutting edge of science and fans and critics alike debate its merits regularly in the press and in blogs. Every day,...
by Natasha Davie | Aug 16, 2012
The health-care landscape is changing: the previous model of the blockbuster pharmaceutical is being challenged by new therapies that have the potential to offer more effective treatments. In this new contribution to Signals Blog, I describe the present landscape for...
by Paul Krzyzanowski | Jul 17, 2012
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech,...
by Paul Krzyzanowski | May 16, 2012
Commercialization plenary summary: part 4 of 4 The last speaker of the commercialization plenary at the Till and McCulloch Meetings earlier this month was Dr. Stephen Minger from GE Healthcare, who shared GE’s perspective regarding the therapeutic and research...
by Paul Krzyzanowski | May 4, 2012
Commercialization plenary summary: part 3 of 4 On day two (May 1) of the Till and McCulloch Meetings, Dr. Emily Culme-Seymour from the London Regenerative Medicine Network introduced work that leverages previous clinical trial information to support future cell...
Comments